Adrenomed’s drug study in patients with early septic shock successfully passes interim analysis


Potsdam/Hennigsdorf - April 2019. Adrenomed AG, a biopharmaceutical company, announced at the end of March 2019 that the Phase II study of the medication Adrecizumab in patients with early septic shock can be continued as planned following a positive interim analysis of 150 patient data. The decision was made after the evaluation of the Sepsis Support Index (SSI), a secondary efficacy endpoint, indicating a positive outcome for the entire study.

Adrecizumab is a monoclonal antibody that forms the basis for a novel approach to treating life-threatening diseases by binding the vasoprotective hormone adrenomedullin.

"Sepsis affects millions of people worldwide every year, with an ongoing high mortality rate of about 30 percent. If the patient has developed a septic shock due to loss of vascular integrity, the mortality rate increases significantly. Currently, patients diagnosed with this life-threatening disease have limited treatment options," said Dr. Jens Zimmermann, Chief Medical Officer of Adrenomed. "We are very encouraged by the positive result of the interim analysis of AdrenOSS-II and we are pleased to see the study continued."

Further information can be found in the press release on the right side of the download area.

About Adrenomed AG

Adrenomed AG is a privately-financed, biopharmaceutical company from Germany with clinical development projects. Adrenomed is pursuing a new therapeutic approach to ensuring the integrity and barrier function of blood vessels. These can become more permeable in severe diseases that are not yet treatable, such as sepsis and acute heart failure, leading to life-threatening edema and shock. The company was founded in 2009 and is led by a management team with decades of experience in the indication of sepsis and profound knowledge in diagnostics and drug development. The company's main product candidate is the monoclonal antibody Adrecizumab, which is already in clinical development. Adrecizumab, the first representative of a new class of therapy, targets the vasoprotective peptide adrenomedullin, a major regulator of vascular integrity. It is currently being clinically evaluated in a biomarker-controlled, double-blind, placebo-controlled, randomized, multicenter proof-of-concept Phase II study of 300 patients in the indication of septic shock. Excellent safety and tolerability have been demonstrated in two Phase I studies.

For more information, visit: see www.brandenburg-kapital.de and www.adrenomed.com

Ansprechpartner


Petra Quehl Project Coordinator